The following is a summary of “Risks of adverse events with mirtazapine for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis,” published in the January 2025 issue of Psychiatry by Kamp et al.

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of interest in everyday activities, appetite changes, sleep disturbances and, in extreme cases,

A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle may also confer beneficial mental health outcomes. The small trial demonstrated how adding creatine to a course of cognitive behavioural therapy can lead to greater

I’ve been living with depression for almost 12 years. I’m 31 now and I found out I had major depressive disorder when I was 19. I had a miserable freshman year of college, but I didn't really ...

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet Psychiatry.

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of major depressive disorder (MDD),

The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for the MM120 program in GAD,

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.

People with bipolar I disorder have had at least one manic episode preceded or followed by hypomanic or major depressive episodes.

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.